LUND, Sweden, June 4, 2019 /PRNewswire/ -- Camurus announces that the leading drug dependence journal Addiction has today published full results from a 48-week, open-label, global Phase 3 study of ...

Camurus (OTC:CAMRF) is a biopharmaceutical company that develops and commercializes medicines for severe and chronic diseases globally. While Eli Lilly and Company (NYSE:LLY) discovers, develops ...

Camurus (NASDAQ STO: CAMX) today announced topline results from the 12-month, randomized, double-blind, placebo-controlled POSITANO Phase 2b study (NCT05281328), evaluating efficacy and safety of ...

Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the ...

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal ® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million ...

Camurus AB (STO:CAMX) presented its first quarter 2025 results on May 15, revealing strong financial performance despite challenging market conditions. The Swedish biopharmaceutical company, which ...

If approved, it could be available as early as March. Braeburn Pharmaceuticals Inc. and Camurus AB on Thursday, July 20 submitted their new drug application to the U.S. Food and Drug ...

Camurus AB will release earnings for the most recent quarter on May 12.Analysts are expecting losses per share of SEK 0.219.Go here to follow Camu ...

CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findingsA follow-up Phase 3 study will be discussed with regulatory authoritiesLUND ...

--Camurus today announced positive, final, topline results from the 52- week Phase 3 open-label ACROINNOVA 2 study, which evaluated safety and efficacy of the company's once-monthly octreotide ...

Camurus maintained its full-year 2025 guidance, projecting revenue between SEK 2.7-3.0 billion (45-61% growth versus 2024) and profit before tax of SEK 0.9-1.2 billion (63-117% growth versus 2024).